CD22 and melanoma: CD22+ infiltrates were found in 37.6% of melanomas (27% cutaneous lesions, 49.1% lymph node metastases, 38% distant metastases), with ~10% of melanomas featuring denser B cell infiltrating populations (>10 cells per high powered field, Fig. 1b,c).